Internet Pioneer In...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$2.74 0.04 | 1.29%
06/04/12 - 03:44 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.71 |
| 52 Week High | 9.89 |
| 52 Week Low | 2.56 |
| Avg. Daily Vol. (Mil) | 0.42 |
| Beta (3 year) | 1.05 |
| Share Related Items | |
| Mkt Cap (Mil) | 231.81 |
| Shares Out (Mil) | 85.54 |
| Float (Mil) | 37.90 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.30 |
| Current Ratio | 5.50 |
| LT Debt/ Equity | 0.26 |
| Total Debt / Equity | 0.29 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 9.52 |
| Price/Book | 2.33 |
| Price/Cash Flow | -2.60 |
| Per Share Data | |
| Earnings | -1.29 |
| Sales | 0.28 |
| Book Value | 1.16 |
| Cash Flow | -1.03 |
| Business Summary | |
|---|---|
| A biopharmaceutical company, which is focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. | |
| General Information | |
| 12481 High Bluff Drive
Suite 200 San Diego, CA 92130 |
|
| www.cadencepharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 220 | |
| CEO: Theodore R. Schroeder | |
| Short Interest | |
| Current Month (Mil) | 6.54 |
| Previous Month (Mil) | 6.88 |
| Short Interest Ratio (Days) | 17.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -62.00 |
| Return on Investments | -72.00 |
| Profitability | |
| Gross Margin | 41.20 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CADX
- Portfolio NameUser Type
- Contributor8 Stocks Below $10 To Avoid
- Contributor10 Most Shorted Stocks in B...
- ContributorRelative Strength Stocks 09...
- Usergrainey Portfolio 1
- Useryourguess Portfolio 1
- Userlives288
- UserCarl Nicola Portfolio 1
- Userron stewart
Latest CADX Headlines from TheStreet
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
- Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge 10.31.11 | 11:10 am
- 5 Stocks Showing Relative Strength in a Weak Market 09.22.11 | 02:09 pm
- Biotech Stock Mailbag: Cadence Pharma 03.11.11 | 07:03 am
- Biotech Sector Weekly Rewind 11.06.10 | 09:11 am
- Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript 11.05.10 | 02:11 pm
- Cadence: When A Drug Approval Sinks Stock 11.03.10 | 10:11 am
- FDA Ends October With Drug Approvals, Rejection 11.01.10 | 07:11 am
- Biotech Stock Mailbag: Exact Sciences 10.15.10 | 07:10 am
- 21 Drugs Facing FDA Approval Decisions 08.31.10 | 08:08 am
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
